
Oxular Ltd raises US$37m
Oxford-based Oxular said it will use the proceeds to finance Phase II studies evaluatingO the company’s lead asset, OXU-001, for the treatment of...

Two companies aim for 2nd-gen COVID vaccines
As scientific papers provide hints that mutants of SARS-CoV-2 that carry the N501Y and E484K mutations are able to reproduce more rapidly as the...

How stress brings cancer to life again
An international research team led by AstraZeneca’s oncology expert Dmitry I. Gabrilovich report that that stressed neutrophils might act as a...

Moderna to file for EU approval of mRNA-1273 vaccine
Modernas primary analysis of the COVE Phase III data was based on 196 cases, of which 185 cases of COVID-19 were observed in the placebo group versus...

German researchers find reason for remdesivir's inefficiency
“We have come to a simple conclusion,” said Max Planck Director Patrick Cramer at the MPI for Biophysical Chemistry. “Remdesivir does interfere with...

Omnix Medical bags €10.8m from EIC Accerator Fund
The money for the trial comes from the EIC Accelerator, for which last year 38 companies with potential breakthrough innovations were selected to...

InteRNA Technologies secures €18.5m in Series B financing
Waterman Ventures and current shareholders Aglaia Oncology Funds and OostNL participated in the funding. The Utrecht-based...